← Eichor
Study identifier: NCT05763706 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Photobiomodulation Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy

Condition: Chemotherapy-induced Peripheral Neuropathy  ·  Sponsor: Jessa Hospital

PhaseNA
Planned participants172
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.

This description comes directly from the study's public registry record.

Talk to the study team

Jeroen Mebis, Prof. Dr.  ·  011 33 72 21  ·  jeroen.mebis@jessazh.be

Marithé Claes, MSc  ·  011 33 72 39  ·  marithe.claes@uhasselt.be

Always discuss trial participation with your own doctor first.

Locations (1)

Jessa HospitalHasselt, Limburg, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05763706